Conserved molecular mechanisms underlying the effects of small molecule xenobiotic chemotherapeutics on cells
- Authors:
- Hemant Sarin
-
Affiliations: Freelance Investigator in Translational Science and Medicine, Charleston, WV 25314, USA - Published online on: December 16, 2015 https://doi.org/10.3892/mco.2015.714
- Pages: 326-368
This article is mentioned in:
Abstract
Klassen CD and Watkins IB III: Casarett and Doull's Essentials of Toxicology. New York, NY: McGraw-Hill. 2010. View Article : Google Scholar | |
Matsumura Y and Maeda H: A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent Smancs. Cancer Res. 46:6387–6392. 1986.PubMed/NCBI | |
Sarin H: Recent progress towards development of effective systemic chemotherapy for the treatment of malignant brain tumors. J Transl Med. 7:772009. View Article : Google Scholar : PubMed/NCBI | |
Sarin H: Overcoming the challenges in the effective delivery of chemotherapies to CNS solid tumors. Ther Deliv. 1:289–305. 2010. View Article : Google Scholar : PubMed/NCBI | |
Sarin H: On the future development of optimally-sized lipid-insoluble systemic therapies for CNS solid tumors and other neuropathologies. Recent Patents CNS Drug Discov. 5:239–252. 2010. View Article : Google Scholar | |
Sarin H: Effective transvascular delivery of chemotherapy into cancer cells with imageable nanoparticles in the 7 to 10 nanometer size range. Current Advances in the Medical Application of Nanotechnology. Bentham Science Publishers Ltd. 10–24. 2012. | |
Sarin H: Permeation tt n Silico Pharmacol. 3:52015. View Article : Google Scholar | |
Sarin H: Translational theranostic methodology for diagnostic imaging and the concomitant treatment of malignant solid tumors. Neurovascular Imaging. 1:32015. View Article : Google Scholar | |
Lee CC, Gillies ER, Fox ME, Guillaudeu SJ, Fréchet JM, Dy EE and Szoka FC: A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas. Proc Natl Acad Sci USA. 103:16649–16654. 2006. View Article : Google Scholar : PubMed/NCBI | |
Trédan O, Galmarini CM, Patel K and Tannock IF: Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst. 99:1441–1454. 2007. View Article : Google Scholar : PubMed/NCBI | |
Rosier RN, Teot LA, Hicks DG, Schwartz C, O'Keefe RJ and Puzas JE: Multiple drug resistance in osteosarcoma. Iowa Orthop J. 15:66–73. 1995.PubMed/NCBI | |
Kleinschmidt-Demasters BK, Kang JS and Lillehei KO: The burden of radiation-induced central nervous system tumors, A single institution experience. J Neuropathol Exp Neurol. 65:204–216. 2006. View Article : Google Scholar : PubMed/NCBI | |
Verhoef GE: DeW olf-Peeters C, Ferrant A, Deprez S, Meeus P, Stul M, Zacheé P, Cassiman JJ, Van den Berghe H and Boogaerts MA: Myelodysplastic syndromes with bone marrow fibrosis: A myelodysplastic disorder with proliferative features. Ann Hematol. 63:235–241. 1991. View Article : Google Scholar : PubMed/NCBI | |
Doudican NA, Kumar A, Singh NK, Nair PR, Lala DA, Basu K, Talawdekar AA, Sultana Z, Tiwari KK, Tyagi A, et al: Personalization of cancer treatment using predictive simulation. J Transl Med. 13:432015. View Article : Google Scholar : PubMed/NCBI | |
Pingle SC, Sultana Z, Pastorino S, Jiang P, Mukthavaram R, Chao Y, Bharati IS, Nomura N, Makale M, Abbasi T, et al: In silico modeling predicts drug sensitivity of patient-derived cancer cells. J Transl Med. 12:1282014. View Article : Google Scholar : PubMed/NCBI | |
Peacock JD, Cherba D, Kampfschulte K, Smith MK, Monks NR, Webb CP and Steensma M: Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors. J Transl Med. 11:2132013. View Article : Google Scholar : PubMed/NCBI | |
Sarin H: Pressuromodulation a. a Transl Med. 13:3722015. View Article : Google Scholar | |
Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT and Brock C: Temozolomide: A review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev. 23:35–61. 1997. View Article : Google Scholar : PubMed/NCBI | |
Johnson RE, Campbell RJ and Laws ER Jr: The cytotoxic effect of ethylnitrosourea on the developing rat cerebellum. Histopathology. Acta Neuropathol. 55:257–261. 1981. View Article : Google Scholar : PubMed/NCBI | |
Kolarić K, Roth A and Fuss V: Combination chemotherapy with 1-methyl-1-nitrosourea and cyclophosphamide in metastatic melanoma. Tumori. 64:89–94. 1978.PubMed/NCBI | |
An Q, Robins P, Lindahl T and Barnes DE: 5-Fluorouracil incorporated into DNA is excised by the Smug1 DNA glycosylase to reduce drug cytotoxicity. Cancer Res. 67:940–945. 2007. View Article : Google Scholar : PubMed/NCBI | |
Tentori L, Forini O, Fossile E, Muzi A, Vergati M, Portarena I, Amici C, Gold B and Graziani G: N3-methyladenine induces early poly(ADP-ribosylation), reduction of nuclear factor-kappa B DNA binding ability, and nuclear up-regulation of telomerase activity. Mol Pharmacol. 67:572–581. 2005. View Article : Google Scholar : PubMed/NCBI | |
Paine PL, Moore LC and Horowitz SB: Nuclear envelope permeability. Nature. 254:109–114. 1975. View Article : Google Scholar : PubMed/NCBI | |
Rostovtseva T and Colombini M: VDAC channels mediate and gate the flow of ATP: Implications for the regulation of mitochondrial function. Biophys J. 72:1954–1962. 1997. View Article : Google Scholar : PubMed/NCBI | |
Colombini M, Yeung CL, Tung J and König T: The mitochondrial outer membrane channel, VDAC, is regulated by a synthetic polyanion. Biochim Biophys Acta. 905:279–286. 1987. View Article : Google Scholar : PubMed/NCBI | |
Nobel PS: Mitochondrial permeability for alcohols aldoses, and amino acids. J Membr Biol. 12:287–299. 1973. View Article : Google Scholar : PubMed/NCBI | |
Kanzawa T, Germano IM, Komata T, Ito H, Kondo Y and Kondo S: Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ. 11:448–457. 2004. View Article : Google Scholar : PubMed/NCBI | |
Griffin RJ, Arris CE, Bleasdale C, Boyle FT, Calvert AH, Curtin NJ, Dalby C, Kanugula S, Lembicz NK, Newell DR, et al: Resistance-modifying agents. 8. Inhibition of O(6)-alkylguanine-DNA alkyltransferase by O(6)-alkenyl-, O(6)-cycloalkenyl-, and O(6)-(2-oxoalkyl)guanines and potentiation of temozolomide cytotoxicity in vitro by O(6)-(1-cyclopentenylmethyl)guanine. J Med Chem. 43:4071–4083. 2000. View Article : Google Scholar : PubMed/NCBI | |
Long L and Dolan ME: Role of cytochrome P450 isoenzymes in metabolism of O(6)-benzylguanine: Implications for dacarbazine activation. Clin Cancer Res. 7:4239–4244. 2001.PubMed/NCBI | |
Ortiz de and Montellano PR: Cytochrome P450-activated prodrugs. Future Med Chem. 5:213–228. 2013. View Article : Google Scholar : PubMed/NCBI | |
Meyer RP, Podvinec M and Meyer UA: Cytochrome P450 CYP1A1 accumulates in the cytosol of kidney and brain and is activated by heme. Mol Pharmacol. 62:1061–1067. 2002. View Article : Google Scholar : PubMed/NCBI | |
Sangar MC, Anandatheerthavarada HK, Tang W, Prabu SK, Martin MV, Dostalek M, Guengerich FP and Avadhani NG: Human liver mitochondrial cytochrome P450 2D6 - individual variations and implications in drug metabolism. FEBS J. 276:3440–3453. 2009. View Article : Google Scholar : PubMed/NCBI | |
Pletsa V, Valavanis C, van Delft JH, Steenwinkel MJ and Kyrtopoulos SA: DNA damage and mutagenesis induced by procarbazine in lambda lacZ transgenic mice, Evidence that bone marrow mutations do not arise primarily through miscoding by O6-methylguanine. Carcinogenesis. 18:2191–2196. 1997. View Article : Google Scholar : PubMed/NCBI | |
Crook TR, Souhami RL and McLean AE: Cytotoxicity, DNA cross-linking, and single strand breaks induced by activated cyclophosphamide and acrolein in human leukemia cells. Cancer Res. 46:5029–5034. 1986.PubMed/NCBI | |
Weber GF and Waxman DJ: Denitrosation of the anti-cancer drug 1,3-bis(2-chloroethyl)-1-nitrosourea catalyzed by microsomal glutathione S-transferase and cytochrome P450 monooxygenases. Arch Biochem Biophys. 307:369–378. 1993. View Article : Google Scholar : PubMed/NCBI | |
Linfoot PA, Gray JW, Dean PN, Marton LJ and Deen DF: Effect of cell cycle position on the survival of 9L cells treated with nitrosoureas that alkylate, cross-link, and carbamoylate. Cancer Res. 46:2402–2406. 1986.PubMed/NCBI | |
Doroshenko N and Doroshenko P: The glutathione reductase inhibitor carmustine induces an influx of Ca2+ in PC12 cells. Eur J Pharmacol. 497:17–24. 2004. View Article : Google Scholar : PubMed/NCBI | |
Kehrer JP: The effect of BCNU (carmustine) on tissue glutathione reductase activity. Toxicol Lett. 17:63–68. 1983. View Article : Google Scholar : PubMed/NCBI | |
FitzGerald GB, Bauman C, Hussoin MS and Wick MM: 2,4-Dihydroxybenzylamine: A specific inhibitor of glutathione reductase. Biochem Pharmacol. 41:185–190. 1991. View Article : Google Scholar : PubMed/NCBI | |
Babson JR and Reed DJ: Inactivation of glutathione reductase by 2-chloroethyl nitrosourea-derived isocyanates. Biochem Biophys Res Commun. 83:754–762. 1978. View Article : Google Scholar : PubMed/NCBI | |
Bizzozero OA and Ziegler JL: DeJ esus G and Bolognani F: Acute depletion of reduced glutathione causes extensive carbonylation of rat brain proteins. J Neurosci Res. 83:656–667. 2006. View Article : Google Scholar : PubMed/NCBI | |
Street JC, Mahmood U, Matei C and Koutcher JA: In vivo and in vitro studies of cyclophosphamide chemotherapy in a mouse mammary carcinoma by 31P NMR spectroscopy. NMR Biomed. 8:149–158. 1995. View Article : Google Scholar : PubMed/NCBI | |
Street JC and Koutcher JA: Effect of radiotherapy and chemotherapy on composition of tumor membrane phospholipids. Lipids. 32:45–49. 1997. View Article : Google Scholar : PubMed/NCBI | |
Jilani K and Lang F: Carmustine-induced phosphatidylserine translocation in the erythrocyte membrane. Toxins (Basel). 5:703–716. 2013. View Article : Google Scholar : PubMed/NCBI | |
Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, Whittle IR, Jääskeläinen J and Ram Z: A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol. 5:79–88. 2003. View Article : Google Scholar : PubMed/NCBI | |
Lambros MP and Rahman YE: Effects of cyclosporin A on model lipid membranes. Chem Phys Lipids. 131:63–69. 2004. View Article : Google Scholar : PubMed/NCBI | |
Birraux J, Kirby JA, Thomason JM and Taylor JJ: The effect of cyclosporin on cell division and apoptosis in human oral keratinocytes. J Periodontal Res. 41:297–302. 2006. View Article : Google Scholar : PubMed/NCBI | |
Bokemeyer D, Kramer HJ and Meyer-Lehnert H: Atrial natriuretic peptide blunts the cellular effects of cyclosporine in smooth muscle. Hypertension. 21:166–172. 1993. View Article : Google Scholar : PubMed/NCBI | |
Raymond MA, Mollica L, Vigneault N, Désormeaux A, Chan JS, Filep JG, Hébert MJ, et al: Blockade of the apoptotic machinery by cyclosporin A redirects cell death toward necrosis in arterial endothelial cells: regulation by reactive oxygen species and cathepsin D. FASEB J. 17:515–517. 2003.PubMed/NCBI | |
Laursen M, Yatime L, Nissen P and Fedosova NU: Crystal structure of the high-affinity Na+K+-ATPase-ouabain complex with Mg2+ bound in the cation binding site. Proc Natl Acad Sci USA. 110:10958–10963. 2013. View Article : Google Scholar : PubMed/NCBI | |
Liu J, Kesiry R, Periyasamy SM, Malhotra D, Xie Z and Shapiro JI: Ouabain induces endocytosis of plasmalemmal Na/K-ATPase in LLC-PK1 cells by a clathrin-dependent mechanism. Kidney Int. 66:227–241. 2004. View Article : Google Scholar : PubMed/NCBI | |
Suwalsky M, Hernandez P, Villena F and Sotomayor CP: The anticancer drug chlorambucil interacts with the human erythrocyte membrane and model phospholipid bilayers. Z Naturforsch C. 54:1089–1095. 1999. View Article : Google Scholar : PubMed/NCBI | |
Krigel R, Liebes LF, Pelle E and Silber R: Chlorambucil therapy in hairy cell leukemia, Effects on lipid composition and lymphocyte subpopulations. Blood. 60:272–275. 1982.PubMed/NCBI | |
Matsura T, Kai M, Jiang J, Babu H, Kini V, Kusumoto C, Yamada K and Kagan VE: Endogenously generated hydrogen peroxide is required for execution of melphalan-induced apoptosis as well as oxidation and externalization of phosphatidylserine. Chem Res Toxicol. 17:685–696. 2004. View Article : Google Scholar : PubMed/NCBI | |
Tilby MJ, Lawley PD and Farmer PB: Alkylation of DNA by melphalan in relation to immunoassay of melphalan-DNA adducts, Characterization of mono-alkylated and cross-linked products from reaction of melphalan with dGMP and GMP. Chem Biol Interact. 73:183–194. 1990. View Article : Google Scholar : PubMed/NCBI | |
Van den Driessche B and Lemière F: VanD ongen W and Esmans EL: Alkylation of DNA by melphalan: Investigation of capillary liquid chromatography-electrospray ionization tandem mass spectrometry in the study of the adducts at the nucleoside level. J Chromatogr B Analyt Technol Biomed Life Sci. 785:21–37. 2003. View Article : Google Scholar : PubMed/NCBI | |
Rodriguez RJ and Acosta D Jr: Inhibition of mitochondrial function in isolated rate liver mitochondria by azole antifungals. J Biochem Toxicol. 11:127–131. 1996. View Article : Google Scholar : PubMed/NCBI | |
Maté MJ, Ortiz-Lombardía M, Boitel B, Haouz A, Tello D, Susin SA, Penninger J, Kroemer G and Alzari PM: The crystal structure of the mouse apoptosis-inducing factor AIF. Nat Struct Biol. 9:442–446. 2002. View Article : Google Scholar : PubMed/NCBI | |
Daugas E, Susin SA, Zamzami N, Ferri KF, Irinopoulou T, Larochette N, Prévost MC, Leber B, Andrews D, Penninger J, et al: Mitochondrio-nuclear translocation of AIF in apoptosis and necrosis. FASEB J. 14:729–739. 2000.PubMed/NCBI | |
Lewis EM, Wilkinson AS, Davis NY, Horita DA and Wilkinson JC: Nondegradative ubiquitination of apoptosis inducing factor (AIF) by X-linked inhibitor of apoptosis at a residue critical for AIF-mediated chromatin degradation. Biochemistry. 50:11084–11096. 2011. View Article : Google Scholar : PubMed/NCBI | |
Wei Y, Fox T, Chambers SP, Sintchak J, Coll JT, Golec JM, Swenson L, Wilson KP and Charifson PS: The structures of caspases-1, −3, −7 and −8 reveal the basis for substrate and inhibitor selectivity. Chem Biol. 7:423–432. 2000. View Article : Google Scholar : PubMed/NCBI | |
Riedl SJ and Shi Y: Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol. 5:897–907. 2004. View Article : Google Scholar : PubMed/NCBI | |
Lindsay J, Esposti MD and Gilmore AP: Bcl-2 proteins and mitochondria - specificity in membrane targeting for death. Biochim Biophys Acta. 1813:532–539. 2011. View Article : Google Scholar : PubMed/NCBI | |
Miyashita T and Reed JC: Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 80:293–299. 1995. View Article : Google Scholar : PubMed/NCBI | |
Cho Y, Gorina S, Jeffrey PD and Pavletich NP: Crystal structure of a p53 tumor suppressor-DNA complex, Understanding tumorigenic mutations. Science. 265:346–355. 1994. View Article : Google Scholar : PubMed/NCBI | |
Billen LP, Shamas-Din A and Andrews DW: Bid A Bax-like BH3 protein. Oncogene. 27((Suppl 1)): S93–S104. 2008. View Article : Google Scholar : PubMed/NCBI | |
Chipuk JE and Green DR: PUMA cooperates with direct activator proteins to promote mitochondrial outer membrane permeabilization and apoptosis. Cell Cycle. 8:2692–2696. 2009. View Article : Google Scholar : PubMed/NCBI | |
Nakano K and Vousden KH: PUMA a novel proapoptotic gene, is induced by p53. Mol Cell. 7:683–694. 2001. View Article : Google Scholar : PubMed/NCBI | |
Loose DS, Kan PB, Hirst MA, Marcus RA and Feldman D: Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes. J Clin Invest. 71:1495–1499. 1983. View Article : Google Scholar : PubMed/NCBI | |
Greenblatt DJ, Zhao Y, Venkatakrishnan K, Duan SX, Harmatz JS, Parent SJ, Court MH and von Moltke LL: Mechanism of cytochrome P450-3A inhibition by ketoconazole. J Pharm Pharmacol. 63:214–221. 2011. View Article : Google Scholar : PubMed/NCBI | |
Ho YS, Tsai PW, Yu CF, Liu HL, Chen RJ and Lin JK: Ketoconazole-induced apoptosis through P53-dependent pathway in human colorectal and hepatocellular carcinoma cell lines. Toxicol Appl Pharmacol. 153:39–47. 1998. View Article : Google Scholar : PubMed/NCBI | |
Wang YJ, Jeng JH, Chen RJ, Tseng H, Chen LC, Liang YC, Lin CH, Chen CH, Chu JS, Ho WL, et al: Ketoconazole potentiates the antitumor effects of nocodazole: In vivo therapy for human tumor xenografts in nude mice. Mol Carcinog. 34:199–210. 2002. View Article : Google Scholar : PubMed/NCBI | |
Pascual A, García I, Conejo C and Perea EJ: Uptake and intracellular activity of fluconazole in human polymorphonuclear leukocytes. Antimicrob Agents Chemother. 37:187–190. 1993. View Article : Google Scholar : PubMed/NCBI | |
Ciccolini J, Fina F, Bezulier K, Giacometti S, Roussel M, Evrard A, Cuq P, Romain S, Martin PM and Aubert C: Transmission of apoptosis in human colorectal tumor cells exposed to capecitabine, Xeloda, is mediated via Fas. Mol Cancer Ther. 1:923–927. 2002.PubMed/NCBI | |
Baltch AL, Smith RP, Ritz WJ, Bopp LH and Michelsen PB: Intracellular activity of voriconazole, fluconazole, and itraconazole against Candida albicans in human monocytes with and without activation by GM-CSF and TNF-alpha. J Appl Res. 5:42005. | |
Murphy JW, Cho Y, Sachpatzidis A, Fan C, Hodsdon ME and Lolis E: Structural and functional basis of CXCL12 (stromal cell-derived factor-1 α) binding to heparin. J Biol Chem. 282:10018–10027. 2007. View Article : Google Scholar : PubMed/NCBI | |
Debnath B, Xu S, Grande F, Garofalo A and Neamati N: Small molecule inhibitors of CXCR4. Theranostics. 3:47–75. 2013. View Article : Google Scholar : PubMed/NCBI | |
Hatse S, Princen K and Bridger G: DeC lercq E and Schols D: Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett. 527:255–262. 2002. View Article : Google Scholar : PubMed/NCBI | |
Pron G, Belehradek J Jr and Mir LM: Identification of a plasma membrane protein that specifically binds bleomycin. Biochem Biophys Res Commun. 194:333–337. 1993. View Article : Google Scholar : PubMed/NCBI | |
Pron G, Belehradek J Jr, Orlowski S and Mir LM: Involvement of membrane bleomycin-binding sites in bleomycin cytotoxicity. Biochem Pharmacol. 48:301–310. 1994. View Article : Google Scholar : PubMed/NCBI | |
Krishan A and Whitlock S: Bleomycin-induced fine structural alterations in cultured mouse fibroblasts and human lymphocytes of neoplastic origin. Cancer Res. 33:777–785. 1973.PubMed/NCBI | |
Pron G, Mahrour N, Orlowski S, Tounekti O, Poddevin B, Belehradek J Jr and Mir LM: Internalisation of the bleomycin molecules responsible for bleomycin toxicity: A receptor-mediated endocytosis mechanism. Biochem Pharmacol. 57:45–56. 1999. View Article : Google Scholar : PubMed/NCBI | |
Ascierto ML, Kmieciak M, Idowu MO, Manjili R, Zhao Y, Grimes M, Dumur C, Wang E, Ramakrishnan V, Wang XY, et al: A signature of immune function genes associated with recurrence-free survival in breast cancer patients. Breast Cancer Res Treat. 131:871–880. 2012. View Article : Google Scholar : PubMed/NCBI | |
Chen L, Huang Z, Yao G, Lyu X, Li J, Hu X, Cai Y, Li W, Li X and Ye C: The expression of CXCL13 and its relation to unfavorable clinical characteristics in young breast cancer. J Transl Med. 13:1682015. View Article : Google Scholar : PubMed/NCBI | |
Stamatopoulos B, Meuleman N, De Bruyn C, Pieters K, Mineur P, Le Roy C, Saint-Georges S, Varin-Blank N, Cymbalista F, Bron D, et al: AMD3100 disrupts the cross-talk between chronic lymphocytic leukemia cells and a mesenchymal stromal or nurse-like cell-based microenvironment: Pre-clinical evidence for its association with chronic lymphocytic leukemia treatments. Haematologica. 97:608–615. 2012. View Article : Google Scholar : PubMed/NCBI | |
Chen LJ, Ye H, Zhang Q, Li FZ, Song LJ, Yang J, Mu Q, Rao SS, Cai PC, Xiang F, et al: Bleomycin induced epithelial-mesenchymal transition (EMT) in pleural mesothelial cells. Toxicol Appl Pharmacol. 283:75–82. 2015. View Article : Google Scholar : PubMed/NCBI | |
Wu Z, Yang L, Cai L, Zhang M, Cheng X, Yang X and Xu J: Detection of epithelial to mesenchymal transition in airways of a bleomycin induced pulmonary fibrosis model derived from an alpha-smooth muscle actin-Cre transgenic mouse. Respir Res. 8:12007. View Article : Google Scholar : PubMed/NCBI | |
Yamada A, Aki T, Unuma K, Funakoshi T and Uemura K: Paraquat induces epithelial-mesenchymal transition-like cellular response resulting in fibrogenesis and the prevention of apoptosis in human pulmonary epithelial cells. PLoS One. 10:e01201922015. View Article : Google Scholar : PubMed/NCBI | |
Dik WA, McAnulty RJ, Versnel MA, Naber BA, Zimmermann LJ, Laurent GJ and Mutsaers SE: Short course dexamethasone treatment following injury inhibits bleomycin induced fibrosis in rats. Thorax. 58:765–771. 2003. View Article : Google Scholar : PubMed/NCBI | |
Domanska UM, Timmer-Bosscha H, Nagengast WB, Munnink Oude TH, Kruizinga RC, Ananias HJ, Kliphuis NM, Huls G, De Vries EG, de Jong IJ, et al: CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy. Neoplasia. 14:709–718. 2012. View Article : Google Scholar : PubMed/NCBI | |
Ujwal R, Cascio D, Colletier JP, Faham S, Zhang J, Toro L, Ping P and Abramson J: The crystal structure of mouse VDAC1 at 2.3 A resolution reveals mechanistic insights into metabolite gating. Proc Natl Acad Sci USA. 105:17742–17747. 2008. View Article : Google Scholar : PubMed/NCBI | |
Catterall WA: Functional subunit structure of voltage-gated calcium channels. Science. 253:1499–1500. 1991. View Article : Google Scholar : PubMed/NCBI | |
Barańska W, Kujawa M and Kujawska E: Influence of vincristine on the Golgi apparatus in preimplantation development of the mouse embryo. Gegenbaurs Morphol Jahrb. 134:175–184. 1988.PubMed/NCBI | |
Kujawa M, Ochocka M and Moskalewski S: Influence of vincristine on the Golgi complex of leukaemic lymphoblasts. Folia Haematologica. 107:193–203. 1980.PubMed/NCBI | |
Carré M, André N, Carles G, Borghi H, Brichese L, Briand C and Braguer D: Tubulin is an inherent component of mitochondrial membranes that interacts with the voltage-dependent anion channel. J Biol Chem. 277:33664–33669. 2002. View Article : Google Scholar : PubMed/NCBI | |
Groninger E, Meeuwsen-De Boer GJ, De Graaf SS, Kamps WA and De Bont ES: Vincristine induced apoptosis in acute lymphoblastic leukaemia cells: A mitochondrial controlled pathway regulated by reactive oxygen species? Int J Oncol. 21:1339–1345. 2002.PubMed/NCBI | |
Eom YW, Kim MA, Park SS, Goo MJ, Kwon HJ, Sohn S, Kim WH, Yoon G and Choi KS: Two distinct modes of cell death induced by doxorubicin, Apoptosis and cell death through mitotic catastrophe accompanied by senescence-like phenotype. Oncogene. 24:4765–4777. 2005. View Article : Google Scholar : PubMed/NCBI | |
Gamen S, Anel A, Lasierra P, Alava MA, Martinez-Lorenzo MJ, Piñeiro A and Naval J: Doxorubicin-induced apoptosis in human T-cell leukemia is mediated by caspase-3 activation in a Fas-independent way. FEBS Lett. 417:360–364. 1997. View Article : Google Scholar : PubMed/NCBI | |
Kuznetsov AV, Margreiter R, Amberger A, Saks V and Grimm M: Changes in mitochondrial redox state, membrane potential and calcium precede mitochondrial dysfunction in doxorubicin-induced cell death. Biochim Biophys Acta. 1813:1144–1152. 2011. View Article : Google Scholar : PubMed/NCBI | |
Mizutani H, Tada-Oikawa S, Hiraku Y, Kojima M and Kawanishi S: Mechanism of apoptosis induced by doxorubicin through the generation of hydrogen peroxide. Life Sci. 76:1439–1453. 2005. View Article : Google Scholar : PubMed/NCBI | |
Wang S, Konorev EA, Kotamraju S, Joseph J, Kalivendi S and Kalyanaraman B: Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms. Histopathology. J Biol Chem. 279:25535–25543. 2004. View Article : Google Scholar : PubMed/NCBI | |
Golomb E, Hill MR, Brown RG and Keiser HR: Ouabain enhances the mitogenic effect of serum in vascular smooth muscle cells. Am J Hypertens. 7:69–74. 1994.PubMed/NCBI | |
Kanai R, Ogawa H, Vilsen B, Cornelius F and Toyoshima C: Crystal structure of a Na+-bound Na+, K+-ATPase preceding the E1P state. Nature. 502:201–206. 2013. View Article : Google Scholar : PubMed/NCBI | |
Aller SG, Yu J, Ward A, Weng Y, Chittaboina S, Zhuo R, Harrell PM, Trinh YT, Zhang Q, Urbatsch IL, et al: Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science. 323:1718–1722. 2009. View Article : Google Scholar : PubMed/NCBI | |
Sehested M, Jensen PB, Skovsgaard T, Bindslev N, Demant EJ, Friche E and Vindeløv L: Inhibition of vincristine binding to plasma membrane vesicles from daunorubicin-resistant Ehrlich ascites cells by multidrug resistance modulators. Br J Cancer. 60:809–814. 1989. View Article : Google Scholar : PubMed/NCBI | |
Srivalli KMR and Lakshmi P: Overview of P-glycoprotein inhibitors: A rational outlook. Braz J Pharm Sci. 48:353–367. 2012. View Article : Google Scholar | |
Chen C, Ke J, Zhou XE, Yi W, Brunzelle JS, Li J, Yong EL, Xu HE and Melcher K: Structural basis for molecular recognition of folic acid by folate receptors. Nature. 500:486–489. 2013. View Article : Google Scholar : PubMed/NCBI | |
Nandini-Kishore SG and Frazier WA: [3H]Methotrexate as a ligand for the folate receptor of Dictyostelium discoideum. Proc Natl Acad Sci USA. 78:7299–7303. 1981. View Article : Google Scholar : PubMed/NCBI | |
Herman S, Zurgil N and Deutsch M: Low dose methotrexate induces apoptosis with reactive oxygen species involvement in T lymphocytic cell lines to a greater extent than in monocytic lines. Inflamm Res. 54:273–280. 2005. View Article : Google Scholar : PubMed/NCBI | |
Ramadan AA, Yousif WB and Ali AM: The effect of methotrexate (MTX) on the small intestine of the mouse. IV. The Golgi apparatus, phosphatases and esterases. Funct Dev Morphol. 2:111–119. 1992.PubMed/NCBI | |
Ramadan AA, Yousif WB and Ali AM: The effect of methotrexate (MTX) on the small intestine of the mouse. Histopathology. Funct Dev Morphol. 2:3–9. 1992.PubMed/NCBI | |
Pritchard DM, Bower L, Potten CS, Jackman AL and Hickman JA: The importance of p53-independent apoptosis in the intestinal toxicity induced by raltitrexed (ZD1694, Tomudex): genetic differences between BALB/c and DBA/2 mice. Clin Cancer Res. 6:4389–4395. 2000.PubMed/NCBI | |
Xue S, Chen YX, Qin SK, Yang AZ, Wang L, Xu HJ and Geng HY: Raltitrexed induces mitochondrial mediated apoptosis in SGC7901 human gastric cancer cells. Mol Med Rep. 10:1927–1934. 2014.PubMed/NCBI | |
Chattopadhyay S, Moran RG and Goldman ID: Pemetrexed Biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther. 6:404–417. 2007. View Article : Google Scholar : PubMed/NCBI | |
Fischer CD: daC osta M and Rothenberg SP: The heterogeneity and properties of folate binding proteins from chronic myelogenous leukemia cells. Blood. 46:855–867. 1975.PubMed/NCBI | |
Fischer CD: DaC osta M and Rothenberg SP: Properties of purified folate-binding proteins from chronic myelogenous leukemia cells. Biochim Biophys Acta. 543:328–339. 1978. View Article : Google Scholar : PubMed/NCBI | |
Barford PA, Blair JA and Malghani MA: The effect of methotrexate on folate metabolism in the rat. Br J Cancer. 41:816–820. 1980. View Article : Google Scholar : PubMed/NCBI | |
Ohbayashi M, Kubota S, Kawase A, Kohyama N, Kobayashi Y and Yamamoto T: Involvement of epithelial-mesenchymal transition in methotrexate-induced pulmonary fibrosis. J Toxicol Sci. 39:319–330. 2014. View Article : Google Scholar : PubMed/NCBI | |
Shprung T and Gozes I: A novel method for analyzing mitochondrial movement: inhibition by paclitaxel in a pheochromocytoma cell model. J Mol Neurosci. 37:254–262. 2009. View Article : Google Scholar : PubMed/NCBI | |
Foland TB, Dentler WL, Suprenant KA, Gupta ML Jr and Himes RH: Paclitaxel-induced microtubule stabilization causes mitotic block and apoptotic-like cell death in a paclitaxel-sensitive strain of Saccharomyces cerevisiae. Yeast. 22:971–978. 2005. View Article : Google Scholar : PubMed/NCBI | |
Salido M, Gonzalez JL and Vilches J: Loss of mitochondrial membrane potential is inhibited by bombesin in etoposide-induced apoptosis in PC-3 prostate carcinoma cells. Mol Cancer Ther. 6:1292–1299. 2007. View Article : Google Scholar : PubMed/NCBI | |
Mizukami S, Kikuchi K, Higuchi T, Urano Y, Mashima T, Tsuruo T and Nagano T: Imaging of caspase-3 activation in HeLa cells stimulated with etoposide using a novel fluorescent probe. FEBS Lett. 453:356–360. 1999. View Article : Google Scholar : PubMed/NCBI | |
Matsushima Y, Kanzawa F, Miyazawa N, Sasaki Y and Saijo N: In vitro antitumor activity of teniposide against carcinoma of the lung in human tumor clonogenic assay. Anticancer Res. 6:921–924. 1986.PubMed/NCBI | |
Sánchez-Alcázar JA, Khodjakov A and Schneider E: Anticancer drugs induce increased mitochondrial cytochrome c expression that precedes cell death. Cancer Res. 61:1038–1044. 2001.PubMed/NCBI | |
Uyar D, Takigawa N, Mekhail T, Grabowski D, Markman M, Lee F, Canetta R, Peck R, Bukowski R and Ganapathi R: Apoptotic pathways of epothilone BMS 310705. Gynecol Oncol. 91:173–178. 2003. View Article : Google Scholar : PubMed/NCBI | |
Thomson AER and Robinson MA: Cytocidal action of colchicine in vitro on lymphocytes in chronic lymphocytic leukaemia. Lancet. 2:868–870. 1967. View Article : Google Scholar : PubMed/NCBI | |
Chen XM, Liu J, Wang T and Shang J: Colchicine-induced apoptosis in human normal liver L-02 cells by mitochondrial mediated pathways. Toxicol In Vitro. 26:649–655. 2012. View Article : Google Scholar : PubMed/NCBI | |
Jelínek M, Balušíková K, Schmiedlová M, Němcová-Fürstová V, Šrámek J, Stančíková J, Zanardi I, Ojima I and Kovář J: The role of individual caspases in cell death induction by taxanes in breast cancer cells. Cancer Cell Int. 15:82015. View Article : Google Scholar : PubMed/NCBI | |
André N, Braguer D, Brasseur G, Gonçalves A, Lemesle-Meunier D, Guise S, Jordan MA and Briand C: Paclitaxel induces release of cytochrome c from mitochondria isolated from human neuroblastoma cells'. Cancer Res. 60:5349–5353. 2000.PubMed/NCBI | |
Khawaja NR, Carré M, Kovacic H, Estève MA and Braguer D: Patupilone-induced apoptosis is mediated by mitochondrial reactive oxygen species through Bim relocalization to mitochondria. Mol Pharmacol. 74:1072–1083. 2008. View Article : Google Scholar : PubMed/NCBI | |
Salim AA, Xiao X, Cho KJ, Piggott AM, Lacey E, Hancock JF and Capon RJ: Rare Streptomyces sp. polyketides as modulators of K-Ras localisation. Org Biomol Chem. 12:4872–4878. 2014. View Article : Google Scholar : PubMed/NCBI | |
Pusceddu S, Indini A and Procopio G: Everolimus treatment in advanced solid tumors: a personal view. Future Science. 2015.OA March 20, (Epub ahead of print) doi:10.4155/fso.14.1. View Article : Google Scholar | |
Chambraud B, Belabes H, Fontaine-Lenoir V, Fellous A and Baulieu EE: The immunophilin FKBP52 specifically binds to tubulin and prevents microtubule formation. FASEB J. 21:2787–2797. 2007. View Article : Google Scholar : PubMed/NCBI | |
Shirane M and Nakayama KI: Inherent calcineurin inhibitor FKBP38 targets Bcl-2 to mitochondria and inhibits apoptosis. Nat Cell Biol. 5:28–37. 2003. View Article : Google Scholar : PubMed/NCBI | |
Tanaka K, Fujita N, Higashi Y and Ogawa N: Neuroprotective and antioxidant properties of FKBP-binding immunophilin ligands are independent on the FKBP12 pathway in human cells. Neurosci Lett. 330:147–150. 2002. View Article : Google Scholar : PubMed/NCBI | |
Simon N, Morin C, Urien S, Tillement JP and Bruguerolle B: Tacrolimus and sirolimus decrease oxidative phosphorylation of isolated rat kidney mitochondria. Br J Pharmacol. 138:369–376. 2003. View Article : Google Scholar : PubMed/NCBI | |
Zini R, Simon N, Morin C, Thiault L and Tillement JP: Tacrolimus decreases in vitro oxidative phosphorylation of mitochondria from rat forebrain. Life Sci. 63:357–368. 1998. View Article : Google Scholar : PubMed/NCBI | |
Zoli W, Ulivi P, Tesei A, Fabbri F, Rosetti M, Maltoni R, Giunchi DC, Ricotti L, Brigliadori G, Vannini I, et al: Addition of 5-fluorouracil to doxorubicin-paclitaxel sequence increases caspase-dependent apoptosis in breast cancer cell lines. Breast Cancer Res. 7:R681–R689. 2005. View Article : Google Scholar : PubMed/NCBI | |
Yang Y, Niu X, Zhang Q, Hao L, Ding Y and Xu H: The efficacy of abraxane on osteosarcoma xenografts in nude mice and expression of secreted protein, acidic and rich in cysteine. Am J Med Sci. 344:199–205. 2012. View Article : Google Scholar : PubMed/NCBI | |
Saif MW: U.S. Food and Drug Administration approves paclitaxel protein-bound particles (Abraxane®) in combination with gemcitabine as first-line treatment of patients with metastatic pancreatic cancer. JOP. 14:686–688. 2013.PubMed/NCBI | |
Coward P, Lee D, Hull MV and Lehmann JM: 4-Hydroxytamoxifen binds to and deactivates the estrogen-related receptor gamma. Proc Natl Acad Sci USA. 98:8880–8884. 2001. View Article : Google Scholar : PubMed/NCBI | |
Richards J, Lim AC, Hay CW, Taylor AE, Wingate A, Nowakowska K, Pezaro C, Carreira S, Goodall J, Arlt W, et al: Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: A rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Res. 72:2176–2182. 2012. View Article : Google Scholar : PubMed/NCBI | |
Darbre PD and King RJB: Differential effects of steroid hormones on parameters of cell growth. Cancer Res. 47:2937–2944. 1987.PubMed/NCBI | |
Yates J and King RJB: Correlation of growth properties and morphology with hormone responsiveness of mammary tumor cells in culture. Cancer Res. 41:258–262. 1981.PubMed/NCBI | |
Talwar GP, Raina K, Gupta JC, Ray R, Wadhwa S and Ali MM: A recombinant luteinising-hormone-releasing- hormone immunogen bioeffective in causing prostatic atrophy. Vaccine. 22:3713–3721. 2004. View Article : Google Scholar : PubMed/NCBI | |
Brandes AA, Ermani M, Turazzi S, Scelzi E, Berti F, Amistà P, Rotilio A, Licata C and Fiorentino MV: Procarbazine and high-dose tamoxifen as a second-line regimen in recurrent high-grade gliomas, A phase II study. J Clin Oncol. 17:645–650. 1999.PubMed/NCBI | |
de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, et al: COU-AA-301 Investigators: Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 364:1995–2005. 2011. View Article : Google Scholar : PubMed/NCBI | |
Kosaka T, Miyajima A, Yasumizu Y, Miyazaki Y, Kikuchi E and Oya M: Limited in vitro efficacy of CYP17A1 inhibition on human castration resistant prostate cancer. Steroids. 92:39–44. 2014. View Article : Google Scholar : PubMed/NCBI | |
Louderbough JMV, Lopez JI and Schroeder JA: Matrix hyaluronan alters epidermal growth factor receptor-dependent cell morphology. Cell Adhes Migr. 4:26–31. 2010. View Article : Google Scholar | |
Hara F, Aoe M, Doihara H, Taira N, Shien T, Takahashi H, Yoshitomi S, Tsukuda K, Toyooka S, Ohta T, et al: Antitumor effect of gefitinib ('Iressa') on esophageal squamous cell carcinoma cell lines in vitro and in vivo. Cancer Lett. 226:37–47. 2005. View Article : Google Scholar : PubMed/NCBI | |
Stegmaier K, Corsello SM, Ross KN, Wong JS, Deangelo DJ and Golub TR: Gefitinib induces myeloid differentiation of acute myeloid leukemia. Blood. 106:2841–2848. 2005. View Article : Google Scholar : PubMed/NCBI | |
Augustin A, Lamerz J, Meistermann H, Golling S, Scheiblich S, Hermann JC, Duchateau-Nguyen G, Tzouros M, Avila DW, Langen H, et al: Quantitative chemical proteomics profiling differentiates erlotinib from gefitinib in EGFR wild-type non-small cell lung carcinoma cell lines. Mol Cancer Ther. 12:520–529. 2013. View Article : Google Scholar : PubMed/NCBI | |
Huang HL, Chen YC, Huang YC, Yang KC, Pan H, Shih SP and Chen YJ: Lapatinib induces autophagy, apoptosis and megakaryocytic differentiation in chronic myelogenous leukemia K562 cells. PLoS One. 6:e290142011. View Article : Google Scholar : PubMed/NCBI | |
Diaz R, Nguewa PA, Parrondo R, Perez-Stable C, Manrique I, Redrado M, Catena R, Collantes M, Peñuelas I, Díaz-González JA, et al: Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model. BMC Cancer. 10:1882010. View Article : Google Scholar : PubMed/NCBI | |
Chen G, Noor A, Kronenberger P, Teugels E, Umelo IA and De Grève J: Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib. PLoS One. 8:e597082013. View Article : Google Scholar : PubMed/NCBI | |
Solca F, Dahl G, Zoephel A, Bader G, Sanderson M, Klein C, Kraemer O, Himmelsbach F, Haaksma E and Adolf GR: Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther. 343:342–350. 2012. View Article : Google Scholar : PubMed/NCBI | |
Stoica GE, Kuo A, Powers C, Bowden ET, Sale EB, Riegel AT and Wellstein A: Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types. J Biol Chem. 277:35990–35998. 2002. View Article : Google Scholar : PubMed/NCBI | |
Sumi Y, Muramatsu H, Hata K, Ueda M and Muramatsu T: Midkine enhances early stages of collagen gel contraction. J Biochem. 127:247–251. 2000. View Article : Google Scholar : PubMed/NCBI | |
Kadomatsu K and Muramatsu T: Midkine and pleiotrophin in neural development and cancer. Cancer Lett. 204:127–143. 2004. View Article : Google Scholar : PubMed/NCBI | |
Friboulet L, Li N, Katayama R, Lee CC, Gainor JF, Crystal AS, Michellys PY, Awad MM, Yanagitani N, Kim S, et al: The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 4:662–673. 2014. View Article : Google Scholar : PubMed/NCBI | |
Lisignoli G, Toneguzzi S, Piacentini A, Cristino S, Grassi F, Cavallo C and Facchini A: CXCL12 (SDF-1) and CXCL13 (BCA-1) chemokines significantly induce proliferation and collagen type I expression in osteoblasts from osteoarthritis patients. J Cell Physiol. 206:78–85. 2006. View Article : Google Scholar : PubMed/NCBI | |
Kalinina OV, Pfeifer N and Lengauer T: Modelling binding between CCR5 and CXCR4 receptors and their ligands suggests the surface electrostatic potential of the co-receptor to be a key player in the HIV-1 tropism. Retrovirology. 10:1302013. View Article : Google Scholar : PubMed/NCBI | |
Massarelli I, Chiellini F, Chiellini E and Bianucci AM: Three-dimensional models of the oligomeric human asialoglycoprotein receptor (ASGP-R). Int J Mol Sci. 11:3867–3884. 2010. View Article : Google Scholar : PubMed/NCBI | |
Fallon RJ and Danaher M: The effect of staurosporine a protein kinase inhibitor, on asialoglycoprotein receptor endocytosis. Exp Cell Res. 203:420–426. 1992. View Article : Google Scholar : PubMed/NCBI | |
Trerè D, Fiume L, De Giorgi LB, Di Stefano G, Migaldi M and Derenzini M: The asialoglycoprotein receptor in human hepatocellular carcinomas: Its expression on proliferating cells. Br J Cancer. 81:404–408. 1999. View Article : Google Scholar : PubMed/NCBI | |
Becherer U, Guatimosim C and Betz W: Effects of staurosporine on exocytosis and endocytosis at frog motor nerve terminals. J Neurosci. 21:782–787. 2001.PubMed/NCBI | |
Belmokhtar CA, Hillion J and Ségal-Bendirdjian E: Staurosporine induces apoptosis through both caspase-dependent and caspase-independent mechanisms. Oncogene. 20:3354–3362. 2001. View Article : Google Scholar : PubMed/NCBI | |
Zhang XD, Gillespie SK and Hersey P: Staurosporine induces apoptosis of melanoma by both caspase-dependent and -independent apoptotic pathways. Mol Cancer Ther. 3:187–197. 2004.PubMed/NCBI | |
Dunai ZA, Imre G, Barna G, Korcsmaros T, Petak I, Bauer PI and Mihalik R: Staurosporine induces necroptotic cell death under caspase-compromised conditions in U937 cells. PLoS One. 7:e419452012. View Article : Google Scholar : PubMed/NCBI | |
Chan KC, Knox WF, Gee JM, Morris J, Nicholson RI, Potten CS and Bundred NJ: Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast. Cancer Res. 62:122–128. 2002.PubMed/NCBI | |
Maity A, Pore N, Lee J, Solomon D and O'Rourke DM: Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3-kinase and distinct from that induced by hypoxia. Cancer Res. 60:5879–5886. 2000.PubMed/NCBI | |
Ouchi T, Monteiro ANA, August A, Aaronson SA and Hanafusa H: BRCA1 regulates p53-dependent gene expression. Proc Natl Acad Sci USA. 95:2302–2306. 1998. View Article : Google Scholar : PubMed/NCBI | |
Arizti P, Fang L, Park I, Yin Y, Solomon E, Ouchi T, Aaronson SA and Lee SW: Tumor suppressor p53 is required to modulate BRCA1 expression. Mol Cell Biol. 20:7450–7459. 2000. View Article : Google Scholar : PubMed/NCBI | |
Andreassen A, Øyjord T, Hovig E, Holm R, Flørenes VA, Nesland JM, Myklebost O, Høie J, Bruland OS, Børresen AL, et al: p53 abnormalities in different subtypes of human sarcomas. Cancer Res. 53:468–471. 1993.PubMed/NCBI | |
O'Hare T, Pollock R, Stoffregen EP, Keats JA, Abdullah OM, Moseson EM, Rivera VM, Tang H, Metcalf CA III, Bohacek RS, et al: Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: Implications for CML. Blood. 104:2532–2539. 2004. View Article : Google Scholar : PubMed/NCBI | |
Grisolano JL, O'Neal J, Cain J and Tomasson MH: An activated receptor tyrosine kinase, TEL/PDGFbetaR, cooperates with AML1/ETO to induce acute myeloid leukemia in mice. Proc Natl Acad Sci USA. 100:9506–9511. 2003. View Article : Google Scholar : PubMed/NCBI | |
Aoki M, Nabeshima K, Koga K, Hamasaki M, Suzumiya J, Tamura K and Iwasaki H: Imatinib mesylate inhibits cell invasion of malignant peripheral nerve sheath tumor induced by platelet-derived growth factor-BB. Lab Invest. 87:767–779. 2007. View Article : Google Scholar : PubMed/NCBI | |
Hercus TR, Thomas D, Guthridge MA, Ekert PG, King-Scott J, Parker MW and Lopez AF: The granulocyte-macrophage colony-stimulating factor receptor, linking its structure to cell signaling and its role in disease. Blood. 114:1289–1298. 2009. View Article : Google Scholar : PubMed/NCBI | |
Ding W, Shanafelt TD, Lesnick CE, Erlichman C, Leis JF, Secreto C, Sassoon TR, Call TG, Bowen DA, Conte M, et al: Akt inhibitor MK2206 selectively targets CLL B-cell receptor induced cytokines, mobilizes lymphocytes and synergizes with bendamustine to induce CLL apoptosis. Br J Haematol. 164:146–150. 2014. View Article : Google Scholar : PubMed/NCBI | |
Zhao Y-Y, Tian Y, Zhang J, Xu F, Yang YP, Huang Y, Zhao HY, Zhang JW, Xue C, Lam MH, et al: Effects of an oral allosteric AKT inhibitor (MK-2206) on human nasopharyngeal cancer in vitro and in vivo. Drug Des Devel Ther. 8:1827–1837. 2014. View Article : Google Scholar : PubMed/NCBI | |
Agarwal E, Chaudhuri A, Leiphrakpam PD, Haferbier KL, Brattain MG and Chowdhury S: Akt inhibitor MK-2206 promotes anti-tumor activity and cell death by modulation of AIF and Ezrin in colorectal cancer. BMC Cancer. 14:1452014. View Article : Google Scholar : PubMed/NCBI | |
Fu YR, Yi ZJ, Yan YR and Qiu ZY: Hydroxycamptothecin-induced apoptosis in hepatoma SMMC-7721 cells and the role of mitochondrial pathway. Mitochondrion. 6:211–217. 2006. View Article : Google Scholar : PubMed/NCBI | |
Uckun FM, Stewart CF, Reaman G, Chelstrom LM, Jin J, Chandan-Langlie M, Waddick KG, White J and Evans WE: In vitro and in vivo activity of topotecan against human B-lineage acute lymphoblastic leukemia cells. Blood. 85:2817–2828. 1995.PubMed/NCBI | |
Caserini C, Pratesi G, Tortoreto M, Bedogné B, Carenini N, Supino R, Perego P, Righetti SC and Zunino F: Apoptosis as a determinant of tumor sensitivity to topotecan in human ovarian tumors, preclinical in vitro/in vivo studies. Clin Cancer Res. 3:955–961. 1997.PubMed/NCBI | |
Kim MK, James J and Annunziata CM: Topotecan synergizes with CHEK1 (CHK1) inhibitor to induce apoptosis in ovarian cancer cells. BMC Cancer. 15:1962015. View Article : Google Scholar : PubMed/NCBI | |
Tolis C, Peters GJ, Ferreira CG, Pinedo HM and Giaccone G: Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines. Eur J Cancer. 35:796–807. 1999. View Article : Google Scholar : PubMed/NCBI | |
Szalay K, Rázga Z and Duda E: TNF inhibits myogenesis and downregulates the expression of myogenic regulatory factors myoD and myogenin. Eur J Cell Biol. 74:391–398. 1997.PubMed/NCBI | |
Fiers W, Beyaert R, Brouckaert P, Everaerdt B, Haegeman C, Suffys P, Tavernier J and Vanhaesebroeck B: TNF Its potential as an antitumour agent. Dev Biol Stand. 69:143–151. 1988.PubMed/NCBI | |
Smith RA and Baglioni C: The active form of tumor necrosis factor is a trimer. J Biol Chem. 262:6951–6954. 1987.PubMed/NCBI | |
Udagawa N, Takahashi N, Jimi E, Matsuzaki K, Tsurukai T, Itoh K, Nakagawa N, Yasuda H, Goto M, Tsuda E, et al: Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: Receptor activator of NF-kappa B ligand. Bone. 25:517–523. 1999. View Article : Google Scholar : PubMed/NCBI | |
Luan X, Lu Q, Jiang Y, Zhang S, Wang Q, Yuan H, Zhao W, Wang J and Wang X: Crystal structure of human RANKL complexed with its decoy receptor osteoprotegerin. J Immunol. 189:245–252. 2012. View Article : Google Scholar : PubMed/NCBI | |
Ciusani E, Croci D, Gelati M, Calatozzolo C, Sciacca F, Fumagalli L, Balzarotti M, Fariselli L, Boiardi A and Salmaggi A: In vitro effects of topotecan and ionizing radiation on TRAIL/Apo2L-mediated apoptosis in malignant glioma. J Neurooncol. 71:19–25. 2005. View Article : Google Scholar : PubMed/NCBI | |
Chen S, Gomez SP, McCarley D and Mainwaring MG: Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment. Cancer Chemother Pharmacol. 49:347–355. 2002. View Article : Google Scholar : PubMed/NCBI | |
Naldini L, Weidner KM, Vigna E, Gaudino G, Bardelli A, Ponzetto C, Narsimhan RP, Hartmann G, Zarnegar R, Michalopoulos GK, et al: Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. EMBO J. 10:2867–2878. 1991.PubMed/NCBI | |
Stamos J, Lazarus RA, Yao X, Kirchhofer D and Wiesmann C: Crystal structure of the HGF beta-chain in complex with the Sema domain of the Met receptor. EMBO J. 23:2325–2335. 2004. View Article : Google Scholar : PubMed/NCBI | |
Paulson AK, Linklater ES, Berghuis BD, App CA, Oostendorp LD, Paulson JE, Pettinga JE and Melnik MK: VandeW oude GF and Graveel CR: MET and ERBB2 are coexpressed in ERBB2+ breast cancer and contribute to innate resistance. Mol Cancer Res. 11:1112–1121. 2013. View Article : Google Scholar : PubMed/NCBI | |
Xie Q, Su Y, Dykema K, Johnson J, Koeman J, De Giorgi V, Huang A, Schlegel R, Essenburg C, Kang L, et al: Overexpression of HGF promotes HBV-induced hepatocellular carcinoma progression and is an effective indicator for Met-targeting therapy. Genes Cancer. 4:247–260. 2013. View Article : Google Scholar : PubMed/NCBI | |
Simonetti S, Molina MA, Queralt C, de Aguirre I, Mayo C, Bertran-Alamillo J, Sanchez JJ, Gonzalez-Larriba JL, Jimenez U, Isla D, et al: Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer. J Transl Med. 8:1352010. View Article : Google Scholar : PubMed/NCBI | |
Maseki S, Ijichi K, Tanaka H, Fujii M, Hasegawa Y, Ogawa T, Murakami S, Kondo E and Nakanishi H: Acquisition of EMT phenotype in the gefitinib-resistant cells of a head and neck squamous cell carcinoma cell line through Akt/GSK-3β/snail signalling pathway. Br J Cancer. 106:1196–1204. 2012. View Article : Google Scholar : PubMed/NCBI | |
Stahtea XN, Roussidis AE, Kanakis I, Tzanakakis GN, Chalkiadakis G, Mavroudis D, Kletsas D and Karamanos NK: Imatinib inhibits colorectal cancer cell growth and suppresses stromal-induced growth stimulation, MT1-MMP expression and pro-MMP2 activation. Int J Cancer. 121:2808–2814. 2007. View Article : Google Scholar : PubMed/NCBI | |
Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K, Ueno Y, Hatch H, Majumder PK, Pan BS, et al: MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther. 9:1956–1967. 2010. View Article : Google Scholar : PubMed/NCBI |